Ascendis Pharma (NasdaqGS:ASND) Update / Briefing Transcript

Ascendis Pharma Conference Call Summary Company Overview - Company: Ascendis Pharma (NasdaqGS:ASND) - Event: Phase 2 Coach Trial Topline Week 52 Data Call - Date: January 08, 2026 Key Points Industry and Company Focus - Industry: Biotechnology, specifically focusing on treatments for achondroplasia and other growth disorders - Core Product: TransCon CNP and TransCon Growth Hormone Combination treatment Core Findings from the Coach Trial - Trial Objective: To evaluate the efficacy and safety of TransCon CNP combined with TransCon Growth Hormone in children with achondroplasia - Patient Cohort: 21 patients enrolled, including treatment-naive and treatment-experienced children [18][19] - Primary Endpoint: Annualized growth velocity at week 52, showing significant improvements [19][22] Efficacy Results - Growth Velocity: - Treatment-naive cohort: 8.8 cm/year, an increase of 3.9 cm/year from baseline [22][23] - Treatment-experienced cohort: 8.42 cm/year, an increase of 3.28 cm/year from baseline [24] - Height Z-scores: - Treatment-naive cohort: Increased from 0.46 to 1.47 [23] - Treatment-experienced cohort: Increased to 2.15 [24] - Comparison to Historical Data: Efficacy significantly exceeds historical benchmarks for achondroplasia treatments [6][7] Safety Profile - Adverse Events: 85% of adverse events were grade 1 (mild) and unrelated to the study drugs [21] - No Cases of Symptomatic Hypotension: Safety profile consistent with individual agents [21][22] - Bone Age: Remained consistent with chronological age, indicating no adverse effects on bone development [22] Additional Benefits - Body Proportionality: Improvements in upper to lower body segment ratios, indicating healthier bone growth [25][26] - Arm Span Growth: Statistically significant increase in arm span, reaching the 84th percentile compared to natural history in achondroplasia [27] Future Directions - Phase 3 Trial Preparation: Ongoing analysis of data to finalize the design of the phase 3 trial, focusing on both linear growth and additional benefits [30][41] - Regulatory Submission: TransCon CNP is under priority review with a PDUFA date of February 28, 2026 [52][81] Market Positioning and Pricing - Combination Therapy: Expected to be positioned as a leading treatment option for achondroplasia, addressing both growth and comorbidities [57][58] - Pricing Strategy: Anticipated to reflect the combined cost of both therapies, with considerations for global market variations [82] Conclusion - Ascendis Pharma is optimistic about the potential of TransCon CNP and TransCon Growth Hormone combination therapy to set a new standard in the treatment of achondroplasia, with significant efficacy and a favorable safety profile. The company is preparing for a phase 3 trial and is confident in the upcoming regulatory approval of TransCon CNP.